查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930115

全球癌症生物標記市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Cancer Biomarkers Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 125 Pages | 商品交期: 請詢問到貨日

價格

癌症生物標記市場的成長驅動因素

全球癌症生物標記市場是腫瘤診斷和治療領域中一個快速發展的細分市場，在癌症早期檢測、治療方案選擇和疾病監測方面發揮關鍵作用。 癌症生物標記是由腫瘤產生或身體內部響應癌症而產生的生物分子，可透過基因組學和蛋白​​質組學技術實現非侵入性且精準的診斷。

市場規模及預測

根據 Fortune Business Insights 預測，2025 年全球癌症生物標記市場規模預計為 428.7 億美元。預計到 2026 年將成長至 482 億美元，到 2034 年將達到 836.1 億美元，在預測期（2026-2034 年）內複合年增長率 (CAGR) 為 7.13%。

這一持續成長反映了癌症發病率的上升、診斷技術的進步以及生物標誌物在個人化醫療和藥物研發中應用範圍的不斷擴大。

市場概覽

癌症生物標記廣泛應用於癌症診斷、預後預測、藥物發現與開發、伴隨診斷和個人化醫療等領域。這些生物標記透過促進早期檢測、評估疾病進展和支持治療決策，顯著改善患者的治療效果。

精準腫瘤學需求的不斷增長以及生物標記在臨床工作流程中的整合，正提升其在全球醫療保健系統中的重要性。此外，學術機構與市場參與者之間的研究合作正在加速生物標記的發現和驗證。

主要市場驅動因子

全球癌症發生率的不斷上升是癌症生物標記市場的主要驅動因素之一，這推動了對早期診斷和標靶治療的需求。生物標記越來越多地應用於疾病風險評估、治療反應評估和伴隨診斷，進一步促進了市場擴張。

此外，強大的研發投入也在推動創新。 根據美國國家醫學圖書館統計，目前約有 1515 種癌症生物標記正在進行臨床試驗，這凸顯了強大的研發管線，預計將在預測期內推動市場成長。

市場限制因子

儘管成長前景強勁，但市場仍面臨諸多挑戰，包括新興國家和已開發國家對生物標記檢測的報銷政策不足。癌症診斷和治療費用高昂，尤其是在發展中國家，這限制了患者獲得生物標記檢測的機會，並促使他們依賴成本更低的替代方案，從而在一定程度上抑制了市場成長。

市場區隔分析

依癌症類型劃分

依癌症類型劃分，市場可細分為乳癌、肺癌、大腸癌、攝護腺癌和其他癌症。

乳癌細分市場佔主導地位，預計到 2026 年將保持 32.59% 的市場佔有率，這主要得益於乳癌的高發病率、公眾意識的提高以及對新型生物標誌物的持續研究。

肺癌細分市場預計在預測期內將以顯著的複合年增長率成長，這主要歸功於研發投入的增加和全球肺癌發生率的上升。

依生物標記類型劃分

依生物標記類型劃分，市場包括 PSA、HER-2、EGFR、KRAS 等。

由於HER-2在乳癌診斷的廣泛應用，預計到2026年，其市佔率將達到33.34%，成為最大的市佔率。預計到2025年，HER-2市佔率將達到142.5億美元。

同時，由於肺癌發生率的上升，預計EGFR生物標記市場佔有率將以更快的速度增長。

依最終使用者劃分

依最終用戶劃分，市場可分為診斷和研究機構、製藥和生物技術公司、醫院和專科診所以及其他機構。

到2026年，診斷和研究機構將佔市場主導地位，市場佔有率將達到53.49%，這主要得益於檢測量的增加和先進診斷試劑盒的推出。由於生物標記在藥物發現和開發中的應用日益廣泛，製藥和生物技術公司也看到了需求的成長。

區域分析

北美將引領全球癌症生物標記市場，2025年市佔率將達35.94%，2026年市場規模將達172.9億美元。預計到2026年，美國市場規模將達到150.3億美元，這得益於先進的診斷技術和強大的研發基礎設施。

歐洲市場規模位居第二，預計到2026年，英國市場規模將達21.9億美元，德國市場規模將達38億美元。

由於醫療保健投資的增加和基於生物標誌物的診斷技術的應用，亞太地區預計將以顯著的複合年增長率增長。 預計到 2026 年，印度市場規模將達到 13.5 億美元，日本市場規模預計將達到 34 億美元。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 主要地區和國家的盛行率/發生率：依癌症類型劃分
  • 主要公司新產品發布狀況
  • 產品線分析：癌症生物標記市場
  • 主要產業趨勢：併購（併購），商業合作

第五章：全球癌症生物標記市場分析：洞察與預測（2021-2034）

  • 主要分析結果/摘要
  • 市場分析、洞察與預測：依癌症類型劃分
    • 肺癌
    • 乳癌
    • 大腸直腸癌
    • 攝護腺癌
    • 其他
  • 市場分析、洞察與預測：依生物標記類型劃分
    • PSA
    • HER-2
    • EGFR
    • KRAS
    • 其他
  • 市場分析、洞察與預測：依最終用戶劃分
    • 製藥和生技公司
    • 診斷與研究機構
    • 醫院和專科醫院診所
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美癌症生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲癌症生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國王國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區癌症生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲癌症生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區美國

第十章：中東與非洲癌症生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第十一章：競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2025）
  • 公司簡介
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • CENTOGENE N.V.
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE N.V.
  • Axon Medchem
  • Sino Biological Inc.
  • R&D;System
  • BioVision Inc.
  • Myriad RBM
  • Other Prominent Players

第 12 章：策略建議

Product Code: FBI100630

Growth Factors of cancer biomarkers Market

The global cancer biomarkers market is a rapidly evolving segment of the oncology diagnostics and therapeutics landscape, playing a critical role in early cancer detection, treatment selection, and disease monitoring. Cancer biomarkers are biological molecules produced by tumors or generated by the body in response to cancer, enabling non-invasive and precise diagnosis through genomics and proteomics technologies.

Market Size and Forecast

According to Fortune Business Insights, the global cancer biomarkers market was valued at USD 42.87 billion in 2025. The market is projected to grow to USD 48.2 billion in 2026 and further reach USD 83.61 billion by 2034, registering a CAGR of 7.13% during the forecast period (2026-2034).

This sustained growth reflects increasing cancer prevalence, technological advancements in diagnostics, and expanding applications of biomarkers in personalized medicine and drug development.

Market Overview

Cancer biomarkers are extensively used across applications such as cancer diagnostics, prognostics, drug discovery and development, companion diagnostics, and personalized medicine. These biomarkers facilitate early disease detection, assess disease progression, and support treatment decision-making, significantly improving patient outcomes.

The increasing demand for precision oncology, along with the integration of biomarkers into clinical workflows, is strengthening their importance across healthcare systems globally. Furthermore, research collaborations between academic institutions and market players are accelerating biomarker discovery and validation.

Key Market Drivers

One of the primary drivers of the cancer biomarkers market is the rising global incidence of cancer, leading to growing demand for early diagnosis and targeted therapies. Biomarkers are increasingly used in disease risk assessment, therapy response evaluation, and companion diagnostics, fueling market expansion.

Additionally, strong research and development investments are driving innovation. According to the U.S. National Library of Medicine, approximately 1,515 cancer biomarkers are currently under clinical trials, highlighting a robust development pipeline that is expected to strengthen market growth during the forecast period.

Market Restraints

Despite strong growth prospects, the market faces challenges such as lack of reimbursement policies for biomarker testing in both emerging and developed economies. The high cost of cancer diagnosis and treatment, particularly in developing countries, limits patient access to biomarker testing and encourages reliance on lower-cost alternatives, restraining market growth to some extent.

Market Segmentation Analysis

By Cancer Type

Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others.

The breast cancer segment dominated the market and is expected to hold a 32.59% share in 2026, driven by high disease prevalence, increased awareness, and ongoing research into novel biomarkers.

The lung cancer segment is anticipated to grow at a significant CAGR during the forecast period due to rising R&D investments and increasing lung cancer incidence globally.

By Biomarker Type

By biomarker type, the market includes PSA, HER-2, EGFR, KRAS, and others.

The HER-2 segment held the largest share, accounting for 33.34% in 2026, supported by its widespread use in breast cancer diagnosis. The HER-2 segment is projected to generate USD 14.25 billion in revenue by 2025.

Meanwhile, the EGFR biomarker segment is expected to grow at a faster pace, driven by increasing lung cancer prevalence.

By End User

Based on end user, the market is segmented into diagnostics & research laboratories, pharmaceutical & biotechnology companies, hospitals & specialty clinics, and others.

The diagnostics & research laboratories segment dominated the market with a 53.49% share in 2026, supported by rising test volumes and introduction of advanced diagnostic kits. Pharmaceutical and biotechnology companies are also witnessing growing demand due to increased use of biomarkers in drug discovery and development.

Regional Analysis

North America dominated the global cancer biomarkers market with a 35.94% share in 2025 and was valued at USD 17.29 billion in 2026. The U.S. market is projected to reach USD 15.03 billion by 2026, supported by advanced diagnostic technologies and strong R&D infrastructure.

Europe follows North America, with the UK projected to reach USD 2.19 billion and Germany USD 3.8 billion by 2026.

The Asia Pacific region is expected to grow at a significant CAGR, driven by increasing healthcare investments and adoption of biomarker-based diagnostics. The India market is projected to reach USD 1.35 billion by 2026, while Japan is expected to reach USD 3.40 billion by 2026.

Competitive Landscape

The cancer biomarkers market is semi-consolidated, with leading players including F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific, Bio-Rad Laboratories, and CENTOGENE N.V. Companies are focusing on new product launches, strategic collaborations, and regulatory approvals to strengthen their market position.

Conclusion

In conclusion, the global cancer biomarkers market is poised for strong growth from USD 42.87 billion in 2025 to USD 83.61 billion by 2034, driven by rising cancer prevalence, expanding applications in personalized medicine, and a strong pipeline of biomarker innovations. Despite reimbursement and cost-related challenges, continued advancements in diagnostics and increased research collaborations are expected to sustain long-term market expansion across developed and emerging regions.

Segmentation By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

By Biomarker Type

  • PSA
  • HER-2
  • EGFR
  • KRAS
  • Others

By End User

  • Pharmaceutical & Biotechnology Companies
  • Diagnostics & Research Laboratories
  • Hospitals & Specialty Clinics
  • Others

By Geography

  • North America (the U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence/ Incidence, by Cancer Type, by Key Regional/ Countries
  • 4.2. New Product Launches, by Key Market Players
  • 4.3. Pipeline Analysis, Cancer Biomarkers
  • 4.4. Key industry Developments - Mergers, Acquisitions and Partnerships

5. Global Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.2.1. Lung Cancer
    • 5.2.2. Breast Cancer
    • 5.2.3. Colorectal Cancer
    • 5.2.4. Prostate Cancer
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Biomarker Type
    • 5.3.1. PSA
    • 5.3.2. HER-2
    • 5.3.3. EGFR
    • 5.3.4. KRAS
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Pharmaceutical & Biotechnology Companies
    • 5.4.2. Diagnostics & Research Laboratories
    • 5.4.3. Hospitals & Specialty Clinics
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.2.1. Lung Cancer
    • 6.2.2. Breast Cancer
    • 6.2.3. Colorectal Cancer
    • 6.2.4. Prostate Cancer
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Biomarker Type
    • 6.3.1. PSA
    • 6.3.2. HER-2
    • 6.3.3. EGFR
    • 6.3.4. KRAS
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Pharmaceutical & Biotechnology Companies
    • 6.4.2. Diagnostics & Research Laboratories
    • 6.4.3. Hospitals & Specialty Clinics
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.2.1. Lung Cancer
    • 7.2.2. Breast Cancer
    • 7.2.3. Colorectal Cancer
    • 7.2.4. Prostate Cancer
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Biomarker Type
    • 7.3.1. PSA
    • 7.3.2. HER-2
    • 7.3.3. EGFR
    • 7.3.4. KRAS
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Pharmaceutical & Biotechnology Companies
    • 7.4.2. Diagnostics & Research Laboratories
    • 7.4.3. Hospitals & Specialty Clinics
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.2.1. Lung Cancer
    • 8.2.2. Breast Cancer
    • 8.2.3. Colorectal Cancer
    • 8.2.4. Prostate Cancer
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Biomarker Type
    • 8.3.1. PSA
    • 8.3.2. HER-2
    • 8.3.3. EGFR
    • 8.3.4. KRAS
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Pharmaceutical & Biotechnology Companies
    • 8.4.2. Diagnostics & Research Laboratories
    • 8.4.3. Hospitals & Specialty Clinics
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.2.1. Lung Cancer
    • 9.2.2. Breast Cancer
    • 9.2.3. Colorectal Cancer
    • 9.2.4. Prostate Cancer
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Biomarker Type
    • 9.3.1. PSA
    • 9.3.2. HER-2
    • 9.3.3. EGFR
    • 9.3.4. KRAS
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Pharmaceutical & Biotechnology Companies
    • 9.4.2. Diagnostics & Research Laboratories
    • 9.4.3. Hospitals & Specialty Clinics
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 10.2.1. Lung Cancer
    • 10.2.2. Breast Cancer
    • 10.2.3. Colorectal Cancer
    • 10.2.4. Prostate Cancer
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Biomarker Type
    • 10.3.1. PSA
    • 10.3.2. HER-2
    • 10.3.3. EGFR
    • 10.3.4. KRAS
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Pharmaceutical & Biotechnology Companies
    • 10.4.2. Diagnostics & Research Laboratories
    • 10.4.3. Hospitals & Specialty Clinics
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.3.1. F. Hoffmann-La Roche Ltd.
      • 11.3.1.1. Overview,
      • 11.3.1.2. Products & services,
      • 11.3.1.3. SWOT analysis,
      • 11.3.1.4. Recent developments,
      • 11.3.1.5. strategies,
      • 11.3.1.6. financials (based on availability)
    • 11.3.2. Abbott
      • 11.3.2.1. Overview,
      • 11.3.2.2. Products & services,
      • 11.3.2.3. SWOT analysis,
      • 11.3.2.4. Recent developments,
      • 11.3.2.5. strategies,
      • 11.3.2.6. financials (based on availability)
    • 11.3.3. CENTOGENE N.V.
      • 11.3.3.1. Overview,
      • 11.3.3.2. Products & services,
      • 11.3.3.3. SWOT analysis,
      • 11.3.3.4. Recent developments,
      • 11.3.3.5. strategies,
      • 11.3.3.6. financials (based on availability)
    • 11.3.4. Bio-Rad Laboratories, Inc.
      • 11.3.4.1. Overview,
      • 11.3.4.2. Products & services,
      • 11.3.4.3. SWOT analysis,
      • 11.3.4.4. Recent developments,
      • 11.3.4.5. strategies,
      • 11.3.4.6. financials (based on availability)
    • 11.3.5. CENTOGENE N.V.
      • 11.3.5.1. Overview,
      • 11.3.5.2. Products & services,
      • 11.3.5.3. SWOT analysis,
      • 11.3.5.4. Recent developments,
      • 11.3.5.5. strategies,
      • 11.3.5.6. financials (based on availability)
    • 11.3.6. Axon Medchem
      • 11.3.6.1. Overview,
      • 11.3.6.2. Products & services,
      • 11.3.6.3. SWOT analysis,
      • 11.3.6.4. Recent developments,
      • 11.3.6.5. strategies,
      • 11.3.6.6. financials (based on availability)
    • 11.3.7. Sino Biological Inc.
      • 11.3.7.1. Overview,
      • 11.3.7.2. Products & services,
      • 11.3.7.3. SWOT analysis,
      • 11.3.7.4. Recent developments,
      • 11.3.7.5. strategies,
      • 11.3.7.6. financials (based on availability)
    • 11.3.8. R&D System
      • 11.3.8.1. Overview,
      • 11.3.8.2. Products & services,
      • 11.3.8.3. SWOT analysis,
      • 11.3.8.4. Recent developments,
      • 11.3.8.5. strategies,
      • 11.3.8.6. financials (based on availability)
    • 11.3.9. BioVision Inc.
      • 11.3.9.1. Overview,
      • 11.3.9.2. Products & services,
      • 11.3.9.3. SWOT analysis,
      • 11.3.9.4. Recent developments,
      • 11.3.9.5. strategies,
      • 11.3.9.6. financials (based on availability)
    • 11.3.10. Myriad RBM
      • 11.3.10.1. Overview,
      • 11.3.10.2. Products & services,
      • 11.3.10.3. SWOT analysis,
      • 11.3.10.4. Recent developments,
      • 11.3.10.5. strategies,
      • 11.3.10.6. financials (based on availability)
    • 11.3.11. Other Prominent Players
      • 11.3.11.1. Overview,
      • 11.3.11.2. Products & services,
      • 11.3.11.3. SWOT analysis,
      • 11.3.11.4. Recent developments,
      • 11.3.11.5. strategies,
      • 11.3.11.6. financials (based on availability)

12. Strategic Recommendation

List of Tables

  • Table 1: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 2: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
  • Table 3: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 4: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 6: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
  • Table 7: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 8: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 10: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
  • Table 11: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 12: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 14: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
  • Table 15: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 18: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
  • Table 19: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 20: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 22: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
  • Table 23: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 24: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cancer Biomarkers Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2025 & 2034
  • Figure 3: Global Cancer Biomarkers Market Forecast (US$ Mn), by Lung Cancer, 2021-2034
  • Figure 4: Global Cancer Biomarkers Market Forecast (US$ Mn), by Breast Cancer, 2021-2034
  • Figure 5: Global Cancer Biomarkers Market Forecast (US$ Mn), by Colorectal Cancer, 2021-2034
  • Figure 6: Global Cancer Biomarkers Market Forecast (US$ Mn), by Prostate Cancer, 2021-2034
  • Figure 7: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 8: Global Cancer Biomarkers Market Value Share (%), by Biomarker Type 2025 & 2034
  • Figure 9: Global Cancer Biomarkers Market Forecast (US$ Mn), by PSA, 2021-2034
  • Figure 10: Global Cancer Biomarkers Market Forecast (US$ Mn), by HER-2, 2021-2034
  • Figure 11: Global Cancer Biomarkers Market Forecast (US$ Mn), by EGFR, 2021-2034
  • Figure 12: Global Cancer Biomarkers Market Forecast (US$ Mn), by KRAS 2021-2034
  • Figure 13: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 14: Global Cancer Biomarkers Market Value Share (%), by End User, 2025 & 2034
  • Figure 15: Global Cancer Biomarkers Market Forecast (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2021-2034
  • Figure 16: Global Cancer Biomarkers Market Forecast (US$ Mn), by Lung Cancer & Research Laboratories, 2021-2034
  • Figure 17: Global Cancer Biomarkers Market Forecast (US$ Mn), by Hospitals & Speciality Clinics, 2021-2034
  • Figure 18: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 19: Global Cancer Biomarkers Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 20: North America Cancer Biomarkers Market Value (US$ Mn), by Cancer Cancer Type, 2025 & 2034
  • Figure 21: North America Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2025
  • Figure 22: North America Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
  • Figure 23: North America Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
  • Figure 24: North America Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 25: North America Cancer Biomarkers Market Value Share (%), by End User, 2025
  • Figure 26: North America Cancer Biomarkers Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 27: North America Cancer Biomarkers Market Value Share (%), By Country, 2025
  • Figure 28: Europe Cancer Biomarkers Market Value (US$ Mn), by Cancer Cancer Type, 2025 & 2034
  • Figure 29: Europe Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2025
  • Figure 30: Europe Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
  • Figure 31: Europe Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
  • Figure 32: Europe Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 33: Europe Cancer Biomarkers Market Value Share (%), by End User, 2025
  • Figure 34: Europe Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 35: Europe Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 36: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2025 & 2034
  • Figure 37: Asia Pacific Cancer Biomarkers Market Value Share (%), by Cancer Type, 2025
  • Figure 38: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
  • Figure 39: Asia Pacific Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
  • Figure 40: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 41: Asia Pacific Cancer Biomarkers Market Value Share (%), by End User, 2025
  • Figure 42: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2025 & 2034
  • Figure 45: Latin America Cancer Biomarkers Market Value Share (%), by Cancer Type, 2025
  • Figure 46: Latin America Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
  • Figure 47: Latin America Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
  • Figure 48: Latin America Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 49: Latin America Cancer Biomarkers Market Value Share (%), by End User, 2025
  • Figure 50: Latin America Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 51: Latin America Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 52: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2025 & 2034
  • Figure 53: Middle East & Africa Cancer Biomarkers Market Value Share (%), by Cancer Type, 2025
  • Figure 54: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
  • Figure 55: Middle East & Africa Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
  • Figure 56: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 57: Middle East & Africa Cancer Biomarkers Market Value Share (%), by End User, 2025
  • Figure 58: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 59: Middle East & Africa Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 60: Global Cancer Biomarkers Market Share (%), By Company, 2025